Hyperosmolarity Triggers the Warburg Effect in Chinese Hamster Ovary Cells and Reveals a Reduced Mitochondria Horsepower.
CHO cells
Warburg effect
hydroxycitrate
hyperosmolarity
lipoic acid
mitochondrial hyperfusion
Journal
Metabolites
ISSN: 2218-1989
Titre abrégé: Metabolites
Pays: Switzerland
ID NLM: 101578790
Informations de publication
Date de publication:
26 May 2021
26 May 2021
Historique:
received:
23
04
2021
accepted:
18
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
3
6
2021
Statut:
epublish
Résumé
Tumor cells are known to favor a glycolytic metabolism over oxidative phosphorylation (OxPhos), which takes place in mitochondria, to produce the energy and building blocks essential for cell maintenance and cell growth. This phenotypic property of tumor cells gives them several advantages over normal cells and is known as the Warburg effect. Tumors can be treated as a metabolic disease by targeting their bioenergetics capacity. Alpha-lipoic acid (ALA) and calcium hydroxycitrate (HCA) are two drugs known to target the Warburg effect in tumor cells and hence induce the mitochondria for ATP production. However, tumor cells, known to have an increased flux through glycolysis, are not able to handle the activation of their mitochondria by drugs or any other condition, leading to decoupling of gene regulation. In this study, these drug effects were studied by mimicking an inflammatory condition through the imposition of a hyperosmotic condition in Chinese hamster ovary (CHO) cells, which behave similarly to tumor cells. Indeed, CHO cells grown in high osmolarity conditions, using 200 mM mannitol, showed a pronounced Warburg effect phenotype. Our results show that hyperosmolar conditions triggered high-throughput glycolysis and enhanced glutaminolysis in CHO cells, such as during cancer cell proliferation in inflammatory tissue. Finally, we found that the hyperosmolar condition was correlated with increased mitochondrial membrane potential (ΔΨm) but mitochondrial horsepower seemed to vanish (h = Δp/ΔΨm), which may be explained by mitochondrial hyperfusion.
Identifiants
pubmed: 34073567
pii: metabo11060344
doi: 10.3390/metabo11060344
pmc: PMC8226498
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Drugs Aging. 2008;25(2):105-18
pubmed: 18257598
Cytotechnology. 2000 Mar;32(3):171-9
pubmed: 19002978
Nat Commun. 2017 Dec 21;8(1):2255
pubmed: 29269878
Annu Rev Biomed Eng. 2017 Jun 21;19:163-194
pubmed: 28301735
Semin Cancer Biol. 2017 Apr;43:134-138
pubmed: 28122260
Gut. 1982 Apr;23(4):326-32
pubmed: 7076010
Biochimie. 2004 Aug;86(8):533-41
pubmed: 15388230
Eye Contact Lens. 2005 Sep;31(5):186-93
pubmed: 16163009
Oncol Lett. 2017 Mar;13(3):1905-1910
pubmed: 28454342
Invest New Drugs. 2012 Feb;30(1):200-11
pubmed: 20931262
Science. 1956 Feb 24;123(3191):309-14
pubmed: 13298683
J Obes. 2011;2011:509038
pubmed: 21197150
Cell Cycle. 2010 Oct 1;9(19):3884-6
pubmed: 20948290
Cancer Lett. 2008 Aug 28;267(2):180-1
pubmed: 18562089
Free Radic Res. 2004 Oct;38(10):1083-92
pubmed: 15512796
Cancer Cell. 2016 Jul 11;30(1):147-160
pubmed: 27411589
Can J Physiol Pharmacol. 2015 Dec;93(12):1021-7
pubmed: 26406389
Oncotarget. 2017 Jun 29;8(38):63551-63561
pubmed: 28969010
Oncogene. 2016 Jul 14;35(28):3619-25
pubmed: 26592449
Ann Intern Med. 1972 Oct;77(4):507-13
pubmed: 4642731
Onco Targets Ther. 2018 Oct 18;11:7229-7243
pubmed: 30425515
Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19345-50
pubmed: 18032601
Expert Rev Clin Pharmacol. 2014 Nov;7(6):837-46
pubmed: 25284345
PLoS One. 2014 Mar 14;9(3):e90832
pubmed: 24632968
Metabolites. 2016 Oct 03;6(4):
pubmed: 27706102
Cancer Res. 2000 Aug 1;60(15):4251-5
pubmed: 10945638
Gene. 2018 Dec 15;678:261-269
pubmed: 30103008
Autophagy. 2012 Apr;8(4):445-544
pubmed: 22966490
Oncotarget. 2017 Feb 14;8(7):10761-10762
pubmed: 28053289
Science. 2009 May 22;324(5930):1029-33
pubmed: 19460998
J Immunother. 2010 May;33(4):335-51
pubmed: 20386472
J Cell Mol Med. 2018 Feb;22(2):738-745
pubmed: 29193856
Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):18868-73
pubmed: 20921411
Cancer Discov. 2018 Feb;8(2):135
pubmed: 29305497
J Inflamm (Lond). 2009 Jun 23;6:21
pubmed: 19549308
Inflamm Res. 2008 Sep;57(9):419-29
pubmed: 18777115
N Biotechnol. 2013 Jan 25;30(2):238-45
pubmed: 22683938
Am J Pathol. 2002 Sep;161(3):987-96
pubmed: 12213727
Curr Top Med Chem. 2018;18(6):494-504
pubmed: 29788892
Diabetol Metab Syndr. 2014 Jul 28;6(1):80
pubmed: 25104975
Nature. 2008 Jul 24;454(7203):436-44
pubmed: 18650914
Sci Rep. 2019 Feb 28;9(1):3153
pubmed: 30816152
Lancet. 2001 Feb 17;357(9255):539-45
pubmed: 11229684
Respir Med. 2003 Aug;97(8):928-32
pubmed: 12924520
Nature. 2002 Dec 19-26;420(6917):860-7
pubmed: 12490959
Am J Physiol Gastrointest Liver Physiol. 2008 Nov;295(5):G934-41
pubmed: 18755808
Ophthalmologe. 2007 Nov;104(11):987-90
pubmed: 18030476
Int J Radiat Biol. 1991 Jul-Aug;60(1-2):85-100
pubmed: 1678003
Toxicol Rep. 2014 Jul 12;1:373-378
pubmed: 28962253
Curr Oncol Rep. 2007 Mar;9(2):109-14
pubmed: 17288875
Eur J Pharm Sci. 2018 May 30;117:41-47
pubmed: 29427700
Ann Med Health Sci Res. 2013 Jul;3(3):442-6
pubmed: 24116330
Oncol Rep. 2015 Sep;34(3):1533-42
pubmed: 26134042
Oncol Rep. 2010 May;23(5):1407-16
pubmed: 20372858
Prog Clin Biol Res. 1996;395:201-9
pubmed: 8895990
Autophagy. 2015;11(8):1198-208
pubmed: 26054373
J Biotechnol. 2013 Apr 15;164(4):469-78
pubmed: 23403402